EGFR and cancer: Antibodies for key signaling pathways (e.g., epidermal growth factor receptor (EGFR), tyrosine‐kinase inhibitors (TKI), human epidermal growth factor receptor‐2 (HER2)),8, 9, 10, 11 inhibitors for vascular endothelial growth factors (VEGF) (e.g., Bevacizumab and Ramucirumab)12, 13, 14 and immune checkpoint inhibitors (e.g., programmed death 1 (PD‐1), programmed death‐ligand 1 (PD‐L1), and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4)),15, 16 have been explored for cancer treatment,17, 18, 19, 20 some of which have revolutionized anticancer therapeutic methods.